New drug injected directly into brain shows promise in early trial for deadly cancer
NCT ID NCT06650605
First seen Apr 07, 2026 · Last updated May 12, 2026 · Updated 8 times
Summary
This early-phase study tested a new drug, I-123 ATT001, given directly into the brain cavity of 7 adults with relapsed glioblastoma, a severe brain cancer. The main goal was to check safety and find the right dose. The study is now complete, and results will help guide future research.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GLIOMA GLIOBLASTOMA MULTIFORME are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
University College London Hosptial
London, United Kingdom
-
University Hospital Southampton
Southampton, United Kingdom
Conditions
Explore the condition pages connected to this study.